High Dose CHOP in Lymphoma

Phase 2

Completed

• Conditions: Non-Hodgkin's Lymphoma

• Registration Number: NCT00192764
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Detailed Description

Not available

Study Timeline

• Study Start: 1996-12
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-19
• Status Verified: 2010-09
• Study Completion: 2010-09
• Last Update Submitted: 2010-09-21
• Last Update Posted: 2010-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• large-cell non-Hodgkin's lymphoma
• IPI low-intermediate, high-intermediate and high or bulky mediastinum
• age 18-65

Exclusion Criteria

• previous treatment for lymphoma
• serious concurrent systemic disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Failure-free survival

Secondary Outcome Measures

Name	Time	Method
response rate
toxicity
overall survival

Trial Locations

Locations (1)

Department of Oncology, Rambam Medical Center; 🇮🇱 Haifa, Israel